Lantheus Holdings, Inc. (LNTH)

Market Cap	5.38B
Revenue (ttm)	1.54B
Net Income (ttm)	254.32M
Shares Out	69.19M
EPS (ttm)	3.53
PE Ratio	22.04
Forward PE	11.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	809,695
Open	78.82
Previous Close	77.83
Day's Range	76.34 - 79.14
52-Week Range	73.11 - 126.89
Beta	0.11
Analysts	Strong Buy
Price Target	133.80 (+71.94%)
Earnings Date	Jul 30, 2025

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 808
• Stock Exchange: NASDAQ
• Ticker Symbol: LNTH
• Website: https://www.lantheus.com

Financial Performance

In 2024, Lantheus Holdings's revenue was $1.53 billion, an increase of 18.32% compared to the previous year's $1.30 billion. Earnings were $312.44 million, a decrease of -4.35%.

Analyst Forecast

According to 5 analysts, the average rating for LNTH stock is "Strong Buy." The 12-month stock price forecast is $133.8, which is an increase of 71.94% from the latest price.

Price Target

$133.8

(71.94% upside)

Analyst Consensus: Strong Buy